OnCo

Hairy cell leukaemia: lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersFRα
Advanced, first line1·
Second line1·
Third line and beyond·1

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersFirst line, symptomaticCladribine (5-7 days) or pentostatin, with rituximab concurrent or delayed (improves MRD-negative CR).83

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersRelapse after >2 yearsRepeat purine analogue + rituximab.83

Third line and beyond

SubgroupSettingApproachProducts and trialsEvidence
FRαEarly relapse or refractoryVemurafenib + rituximab (or dabrafenib-trametinib); ibrutinib; moxetumomab pasudotox where still available; clinical trial.87

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.